In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: The losartan intervention for endpoint reduction in hypertension (LIFE) study

Hypertension

Volumn 50, Issue 5, 2007, Pages 984-990

  Okin, Peter M ^a   Devereux, Richard B ^a   Harris, Katherine E ^b   Jern, Sverker ^c   Kjeldsen, Sverre E ^d   Lindholm, Lars H ^e   Dahlöf, Björn ^c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

Diabetes mellitus; Electrocardiography; Hypertension; Hypertrophy; Prognosis

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; LOSARTAN; ANTIHYPERTENSIVE AGENT;

ADULT; ANAMNESIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; AGED; COMORBIDITY; DRUG EFFECT; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; COMORBIDITY; DIABETES MELLITUS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; LOSARTAN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME;

EID: 35848953186     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.096818     Document Type: Article

References (46)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Heart Study. JAMA. 1979;241:2034-2038.
2. Kleinmann JC, Donahue RP, Harris MI, Finacune FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol. 1988;128:389-401.
3. Howard BV, Rodriguez BL, Bennett PH, Harris MI, Hamman R, Kuller LH, Pearson TA, Wylie-Rosett J. Prevention Conference VI: Diabetes and cardiovascular disease: writing group I: epidemiology. Circulation. 2002;105:e132-e137.
4. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.
5. Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, for the LIFE Study Investigators. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Circulation. 2006;113:1588-1596.
6. Welborn TA, Breckenridge A, Rubenstein AH, Dollery CT, Fraser TR. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet. 1966;1:1336-1337.
7. Serné EH, Stehouwer CDA, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJM, Gans ROB. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation. 1999;99:896-902.
8. Árnlöv J, Pencina MJ, Nam B-H, Meigs JB, Fox CS, Levy D, D'Agostino RB, Vasan RS. Relations of insulin sensitivity to longitudinal blood pressure tracking: variations with baseline age, body mass index, and blood pressure. Circulation. 2005;112:1719-1727.
9. Hu FB, Stampfer MJ. Insulin resistance and hypertension: the chicken-egg question revisisted. Circulation. 2005;112:1678-1680.
10. Am Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26:S80-S82.
11. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension. 1999;33:1130-1134.
12. Sowers JR, Epstain M, Frohlich ED. Diabetes, hypertension and cardiovascular disease. An update. Hypertension. 2001;37:1053-1059.
13. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. for the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342:905-912.
14. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000;342:969-970.
15. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck J-E for the Captopril Prevention Project (CAPPP) study group. Lancet. 1999;353:611-616.
16. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BHR, Zinman B for the HOPE Study Investigators. JAMA. 2001;286:1882-1885.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
18. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-1574.
19. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Piat F, Schork A, Smith B, Zanchetti A for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
20. Zoellick AJ, Gag J, Base S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48:219-224.
21. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
22. Palmieri V, Bella JN, Arnett DR, Liu JE, Oberman A, Schuck M-Y, Kitzman DW, Hopkins PN, Morgan D, Rao DC, Devereux RB. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) Study. Circulation. 2001;103:102-107.
23. Bella JN, Devereux RB, Roman MJ, Palmieri V, Liu JE, Paranicas M, Welty TK, Lee ET, Fabsitz RR, Howard BV and Strong Heart Study Investigators. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in Am Indians (The Strong Heart Study). Am J Cardiol. 2001;87:1260-1265.
24. Phillips RA, Krakoff LR, Dunaif A, Finegood DT, Gorlin R, Schimabukuro S. Relation among LV mass, insulin resistance and BP in non-obese subjects. J Clin Endocrin Metab. 1998;83:4284-4288.
25. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart is diabetes: Part I: General Concepts. Circulation. 2002;105:1727-1733.
26. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Porcellati C. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy. J Am Coll Cardiol. 1998;31:383-390.
27. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
28. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
29. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
30. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
31. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic value of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-2356.
32. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, for the LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and prediction of major cardiovascular events. JAMA. 2004;292:2343-2349.
33. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm L, Nieminen MS, Edelman JM, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation: the LIFE Study. JAMA. 2006;296:1242-1248.
34. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation. 2003;108:684-690.
35. Lindholm LH, Ibsen H, Birch-Johnson K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S, for the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879-1886.
36. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20:1180-1186.
37. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417-423.
38. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161-186.
39. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
40. Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Snapinn S, Dahlöf B. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension. 2004;44:48-54.
41. Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Dahlöf B. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: The LIFE Study. Circulation. 2006;113:67-73.
42. WHO Study Group. Diabetes Mellitus. (Technical report series 727). Geneva: World Health Organization. 1985.
43. World Health Organization (WHO). Department of Noncommunicable Disease Surveillance. Geneva: WHO; 1999, pp. 1-59.
44. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a timevarying covariate with an extended Kaplan-Meier estimate. The Am Statistician. 2005;59:301-307.
45. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of left ventricular hypertrophy: test performance in relation to the definition of hypertrophy and the presence of obesity. J Am Coll Cardiol. 1996;27:124-131.
46. Olsen MH, Possum E, Høieggen A, Wachtell K, Hjerkinn E, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens. 2005;23:891-898.